Boosting CAR-T Cell Therapy with ICIs
Immune checkpoint inhibitors (ICIs) are a class of molecules that target specific biochemical pathways involved in regulating immune responses. These pathways, known as immune checkpoints, [...]
Immune checkpoint inhibitors (ICIs) are a class of molecules that target specific biochemical pathways involved in regulating immune responses. These pathways, known as immune checkpoints, [...]
Successful targeting of cell-surface tumor markers by various methods has made identification of such molecules a potentially high pay-off goal for the creation of new [...]
Great strides have been made in the treatment of B-cell malignancies with Chimeric antigen receptor (CAR) T-cell therapies. Efforts have been less successful when applying [...]
Multiple myeloma (MM) is a complex blood cancer affecting plasma cells. Patients can experience bone damage and fractures, kidney failure resulting from protein buildup, anemia [...]
Glioblastoma multiforme (GBM), the deadliest malignant brain tumor, also represents a large proportion of all cerebral neoplasms1. Despite strides in immunotherapy, including Chimeric Antigen Receptor [...]
CAR T cell therapies have achieved substantial improvements in the prognoses of patients fighting advanced hematological malignancies, demonstrating robust efficacy in inducing durable remissions. While [...]
Chimeric Antigen Receptor (CAR) T cells are the protagonist in the evolving story of adoptive immunotherapy research. The villain in the story is almost always [...]
The advent of CRISPR-Cas9 marked a turning point in the realm of genetics and molecular biology. The technology made gene editing more accessible, efficient, and [...]
CAR-T cells, or chimeric antigen receptor T cells, hold great potential for the treatment of cancer and other diseases. Although several CAR-T therapies have received [...]